Adverse effect

Interquartile range

Surgery

Mycobacterium

Nontuberculous mycobacteria

Mycobacterium abscessus

Mycobacterium avium complex

Regimen

Tuberculosis

Internal medicine

Medicine

Pathology

Open Forum Infectious Diseases

Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2–11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.

Preliminary, Real-world, Multicenter Experience With Omadacycline for <i>Mycobacterium abscessus</i> Infections

Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections